Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.
Terns Pharmaceuticals, Inc. (NASDAQ: TERN) is a clinical-stage biopharmaceutical company advancing novel small molecule therapies for liver diseases, oncology, obesity, and hematologic disorders. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments.
Investors and researchers will find timely updates on TERN-701 (chronic myeloid leukemia therapy), metabolic disorder candidates, and regulatory milestones. Our curated news collection includes:
• Clinical trial progress reports
• FDA submission updates
• Research partnership announcements
• Financial results disclosures
All content is sourced directly from company filings and verified press releases. Bookmark this page to monitor Terns' innovative work in molecularly-targeted therapies and capital-efficient drug development.
Terns Pharmaceuticals, Inc. reported its first quarter 2024 financial results and corporate updates, highlighting the progress on its two lead programs, TERN-701 for CML and TERN-601 for obesity. The company has a cash position of $241 million expected to last into 2026. Recent developments include positive findings from the Phase 1 study of TERN-701 and the progress of TERN-601's first-in-human trial. The company also announced key appointments in its leadership team. Financially, Terns reported a net loss of $22.4 million for Q1 2024, with R&D expenses of $18.6 million and G&A expenses of $6.9 million.
Terns Pharmaceuticals, Inc. announced the appointment of Scott Harris as chief development officer and the departure of Erin Quirk, M.D., president, head of research and development. Dr. Quirk will be leaving the company to pursue other opportunities. Mr. Harris will oversee various operations, and key executives will now report directly to the CEO. The company expressed gratitude to Dr. Quirk for her contributions and confidence in the leadership team's ability to advance their pipeline. Mr. Harris brings over 25 years of experience in drug development and is optimistic about Terns' future.
Terns Pharmaceuticals, a clinical-stage biopharmaceutical company, will participate in The Citizens JMP Life Sciences Conference 2024. Senior management will join a fireside chat to discuss the company's small-molecule product candidates for serious diseases like oncology and obesity. The event will be live webcasted on May 14, 2024, at 1:30 p.m. ET, with a replay available for 30 days.
Terns Pharmaceuticals, Inc. announced the granting of an equity inducement award to Melita Sun Jung, the new Chief Business Officer, under the terms of the Inducement Plan. The award includes an option to purchase 475,000 shares of Terns common stock at an exercise price of $5.08 per share, with a 10-year term and vesting over four years.
Terns Pharmaceuticals, a biopharmaceutical company, announces positive data from a Phase 1 study of TERN-701, a potential BCR-ABL inhibitor for CML treatment, showing no food effect on dosing. The ongoing study in healthy volunteers displayed promising results, supporting once-daily dosing with or without food. The company aims to differentiate TERN-701 from the current standard, asciminib, by offering more convenient dosing options. Phase 1 CARDINAL trial is ongoing, with interim data expected in late 2024.
FAQ
What is the current stock price of Terns Pharmaceuticals (TERN)?
What is the market cap of Terns Pharmaceuticals (TERN)?
